세계의 정신분열증 치료제 시장 보고서(2025년)

Schizophrenia medications are designed to alleviate the symptoms of schizophrenia, a chronic mental disorder that impacts thoughts, perceptions, emotions, and social interactions. These drugs work by addressing chemical imbalances in the brain, particularly those involving dopamine and serotonin, which helps reduce psychotic symptoms, stabilize mood, and improve cognitive abilities, leading to better daily functioning and increased independence.

The primary therapeutic categories of schizophrenia drugs include second-generation, third-generation, and other types. Second-generation antipsychotics, also known as atypical antipsychotics, treat schizophrenia by targeting dopamine and serotonin receptors. These drugs provide symptom relief with a reduced risk of movement disorders compared to first-generation antipsychotics. They are available in various forms, such as oral and injectable, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The schizophrenia drugs market research report is one of a series of new reports from The Business Research Company that provides schizophrenia drugs market statistics, including the schizophrenia drugs industry global market size, regional shares, competitors with the schizophrenia drugs market share, detailed schizophrenia drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the schizophrenia drugs industry. These schizophrenia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The schizophrenia drugs market size has grown strongly in recent years. It will grow from $7.96 billion in 2024 to $8.41 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to the emergence of newer drugs such as second and third-generation antipsychotics, an increase in the prevalence of mental disturbances and schizophrenia, a rise in awareness about mental health, a surge in mental health awareness programs by government and non-government organizations, rise in the number of geriatric populations.

The schizophrenia drugs market size is expected to see strong growth in the next few years. It will grow to $10.61 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to the increasing need for better and effective treatment outcomes, increase in research and development activity for advancements in antipsychotic drugs, product launches, and product approvals, growing investments in the development of novel pharmaceuticals for mental health issues, better insurance coverage for mental health treatments, government initiatives, and support. Major trends in the forecast period include the development of long-acting injectable formulations, the introduction of digital tools, such as mobile apps and wearables, the emergence of drugs targeting glutamatergic pathways, utilization of genetic and biomarker research, and a growing focus on adjunct therapies.

The forecast of 6.0% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade disputes may burden U.S. psychiatric facilities by increasing prices of atypical antipsychotics and long-acting injectable formulations imported from Belgium and Ireland, potentially compromising mental health treatment and raising behavioral healthcare costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing number of schizophrenia cases is expected to drive the growth of the schizophrenia drugs market. Schizophrenia is a chronic mental disorder characterized by distorted thoughts, perceptions, emotions, and behaviors, often leading to hallucinations and delusions. Factors such as genetic predisposition, environmental stressors, substance abuse, and imbalances in brain chemistry are contributing to the rise in schizophrenia cases. Schizophrenia medications help manage symptoms, reducing the disorder's impact on patients' daily lives and improving overall treatment outcomes. For example, in February 2024, the National Library of Medicine, a US-based biomedical library, reported that the prevalence of schizophrenia and related psychotic disorders in the US population ranged from 0.25% to 0.64%. Additionally, in January 2024, the British Columbia Schizophrenia Society, a nonprofit organization based in Canada, stated that schizophrenia is a leading cause of hospitalization for mental illnesses, accounting for 19.9% of general hospital admissions and 30.9% of psychiatric hospital stays. As a result, the increasing number of schizophrenia cases will fuel the growth of the schizophrenia drugs market.

Leading companies in the schizophrenia drugs market are focused on developing advanced treatments, such as oral medications for schizophrenia, to improve patient care and treatment outcomes. Oral medications for schizophrenia are taken by mouth to manage the symptoms of the disorder, typically involving antipsychotics that help stabilize mood, thoughts, and perceptions. For example, in September 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Cobenfy, an innovative oral medication for treating schizophrenia in adults. This groundbreaking drug combines xanomeline and trospium chloride, offering a new approach compared to traditional antipsychotics by targeting cholinergic receptors rather than dopamine receptors. This unique mechanism has the potential to alleviate symptoms such as delusions and disorganized thinking while minimizing the common side effects associated with older antipsychotic medications, making Cobenfy a promising alternative in schizophrenia treatment.

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. This acquisition is expected to enhance Bristol Myers Squibb's neuroscience portfolio by adding KarXT, a new antipsychotic, and expanding its pipeline with potential treatments for schizophrenia, Alzheimer's disease, and other mental health disorders. Karuna Therapeutics, a US-based biopharmaceutical company, specializes in producing drugs for schizophrenia.

Major players in the schizophrenia drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co., Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., Sun Pharmaceutical Industries Ltd., AbbVie Inc., H. Lundbeck A/S, Cipla Ltd., Lupin Limited, Alkermes plc, Vanda Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Mylan NV, Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Holdings Inc., Lifegenix, and Flagship Biotech International Pvt. Ltd.

North America was the largest region in the schizophrenia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in schizophrenia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the schizophrenia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The schizophrenia drugs market consists of sales of transdermal patches, liquid formulations, and adjunctive therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Schizophrenia Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on schizophrenia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for schizophrenia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The schizophrenia drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutic Class: Second Generation; Third Generation; Other Therapeutic Classes
• 2) By Treatment: Oral; Injectable
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Second Generation: Risperidone; Olanzapine; Quetiapine; Aripiprazole; Paliperidone; Ziprasidone; Others
• 2) By Third Generation: Brexpiprazole; Cariprazine; Others
• 3) By Other Therapeutic Classes: First-Generation Antipsychotics; Combination Therapies; Others
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co.; Novartis AG; Sanofi S.A.; Bristol Myers Squibb; AstraZeneca PLC; Eli Lilly and Company; Amgen Inc.; F. Hoffmann-La Roche Ltd.; Teva Pharmaceutical Industries Ltd.; UCB S.A.; Sun Pharmaceutical Industries Ltd.; AbbVie Inc.; H. Lundbeck A/S; Cipla Ltd.; Lupin Limited; Alkermes plc; Vanda Pharmaceuticals Inc.; Sumitomo Pharma Co. Ltd.; Mylan NV; Otsuka Pharmaceutical Co. Ltd.; Reviva Pharmaceuticals Holdings Inc.; Lifegenix; Flagship Biotech International Pvt. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Schizophrenia Drugs Market Characteristics

3. Schizophrenia Drugs Market Trends And Strategies

4. Schizophrenia Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Schizophrenia Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Schizophrenia Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Schizophrenia Drugs Market Growth Rate Analysis
• 5.4. Global Schizophrenia Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Schizophrenia Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Schizophrenia Drugs Total Addressable Market (TAM)

6. Schizophrenia Drugs Market Segmentation

• 6.1. Global Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Second Generation
• Third Generation
• Other Therapeutic Classes
• 6.2. Global Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Schizophrenia Drugs Market, Sub-Segmentation Of Second Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Risperidone
• Olanzapine
• Quetiapine
• Aripiprazole
• Paliperidone
• Ziprasidone
• Others
• 6.5. Global Schizophrenia Drugs Market, Sub-Segmentation Of Third Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brexpiprazole
• Cariprazine
• Others
• 6.6. Global Schizophrenia Drugs Market, Sub-Segmentation Of Other Therapeutic Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Generation Antipsychotics
• Combination Therapies
• Others

7. Schizophrenia Drugs Market Regional And Country Analysis

• 7.1. Global Schizophrenia Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Schizophrenia Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Schizophrenia Drugs Market

• 8.1. Asia-Pacific Schizophrenia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Schizophrenia Drugs Market

• 9.1. China Schizophrenia Drugs Market Overview
• 9.2. China Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Schizophrenia Drugs Market

• 10.1. India Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Schizophrenia Drugs Market

• 11.1. Japan Schizophrenia Drugs Market Overview
• 11.2. Japan Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Schizophrenia Drugs Market

• 12.1. Australia Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Schizophrenia Drugs Market

• 13.1. Indonesia Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Schizophrenia Drugs Market

• 14.1. South Korea Schizophrenia Drugs Market Overview
• 14.2. South Korea Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Schizophrenia Drugs Market

• 15.1. Western Europe Schizophrenia Drugs Market Overview
• 15.2. Western Europe Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Schizophrenia Drugs Market

• 16.1. UK Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Schizophrenia Drugs Market

• 17.1. Germany Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Schizophrenia Drugs Market

• 18.1. France Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Schizophrenia Drugs Market

• 19.1. Italy Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Schizophrenia Drugs Market

• 20.1. Spain Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Schizophrenia Drugs Market

• 21.1. Eastern Europe Schizophrenia Drugs Market Overview
• 21.2. Eastern Europe Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Schizophrenia Drugs Market

• 22.1. Russia Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Schizophrenia Drugs Market

• 23.1. North America Schizophrenia Drugs Market Overview
• 23.2. North America Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Schizophrenia Drugs Market

• 24.1. USA Schizophrenia Drugs Market Overview
• 24.2. USA Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Schizophrenia Drugs Market

• 25.1. Canada Schizophrenia Drugs Market Overview
• 25.2. Canada Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Schizophrenia Drugs Market

• 26.1. South America Schizophrenia Drugs Market Overview
• 26.2. South America Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Schizophrenia Drugs Market

• 27.1. Brazil Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Schizophrenia Drugs Market

• 28.1. Middle East Schizophrenia Drugs Market Overview
• 28.2. Middle East Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Schizophrenia Drugs Market

• 29.1. Africa Schizophrenia Drugs Market Overview
• 29.2. Africa Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Schizophrenia Drugs Market Competitive Landscape And Company Profiles

• 30.1. Schizophrenia Drugs Market Competitive Landscape
• 30.2. Schizophrenia Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Schizophrenia Drugs Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb
• 31.2. AstraZeneca PLC
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. F. Hoffmann-La Roche Ltd.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. UCB S.A.
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. AbbVie Inc.
• 31.10. H. Lundbeck A/S
• 31.11. Cipla Ltd.
• 31.12. Lupin Limited
• 31.13. Alkermes plc
• 31.14. Vanda Pharmaceuticals Inc.
• 31.15. Sumitomo Pharma Co. Ltd.

32. Global Schizophrenia Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Schizophrenia Drugs Market

34. Recent Developments In The Schizophrenia Drugs Market

35. Schizophrenia Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Schizophrenia Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Schizophrenia Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Schizophrenia Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer